Recent advancements in Generative Artificial Intelligence are set to transform the biotechnology sector. Amgen’s CTO, David Reese, describes this era as a pivotal moment, merging technology and biotech to enhance drug discovery, manufacturing, and commercialization. Amgen is committed to expediting the delivery of innovative therapies while empowering employees with state-of-the-art tools.
The company embraced OpenAI’s ChatGPT Enterprise, facilitating a phased rollout that allowed for secure integration into meaningful workflows. Sean Bruich, Amgen’s SVP of Artificial Intelligence and Data, notes the substantial impacts of OpenAI’s latest model, GPT-5. Internal evaluations revealed significant improvements in accuracy and reliability, coupled with positive qualitative feedback regarding output quality. This progress not only boosts existing workflows but also paves the way for new applications, crucial for maintaining Amgen’s high standards in scientific accuracy. Overall, the integration of AI represents a significant leap toward fulfilling Amgen’s mission to serve patients better.
Source link
